Outlook Therapeutics (OTLK) Non Operating Interest Expenses (2015 - 2023)

Outlook Therapeutics (OTLK) has reported Non Operating Interest Expenses for 8 consecutive years, with $206.0 the latest figure, recorded in Q3 2023.

• On a quarterly basis, Non Operating Interest Expenses changed N/A year-over-year to $206.0 in Q3 2023; TTM through Sep 2024 was $509.0, a 99.88% decrease from a year earlier, with the FY2024 full-year figure at $3.2 million, up 24.72% from the prior year.
• Non Operating Interest Expenses was $206.0 for Q3 2023 at Outlook Therapeutics, down from $303.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $1.1 million in Q2 2019 and troughed at $206.0 in Q3 2023.
• A 4-year average of $410262.8 and a median of $250409.0 in 2021 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses advanced 14.44% in 2019 and slumped 90.95% in 2020, its largest moves.
• Over 4 years, Non Operating Interest Expenses stood at $597665.0 in 2019, then sank by 73.29% to $159663.0 in 2020, then soared by 56.84% to $250409.0 in 2021, then plunged by 99.92% to $206.0 in 2023.
• The last three Non Operating Interest Expenses figures came in at $206.0 (Q3 2023), $303.0 (Q2 2023), and $250409.0 (Q1 2021), per Business Quant data.